Home › Pharmacology › Hypoglycemic Agents

Hypoglycemic Agents

For medical students2 min readUpdated 2026-10-10

Hypoglycemic agents are pharmacological drugs designed to lower blood glucose levels. They form the foundation of diabetes mellitus therapy, encompassing both hormone replacement therapy and various synthetic oral agents.

BiguanidesImprove tissue sensitivity to insulin without stimulating its secretion.

Insulin TargetSpecific receptors that trigger the translocation of GLUT-4 transporters to the membrane.

AntagonistsGlucagon preparations increase blood sugar and are used to treat severe hypoglycemia.

MeglitinidesAct briefly to prevent sharp blood sugar spikes immediately after meals.

Classification of Diabetes Medications

All drugs used in diabetology can be divided into two groups with opposite effects. The main pool consists of hypoglycemic agents, which lower blood sugar levels. These include:

Insulin preparations. This is essential replacement therapy, which is life-saving in type 1 diabetes and may also be prescribed in type 2 diabetes.
Synthetic oral agents. A vast group of drugs classified by their site of action and effect on hormone secretion (sulfonylureas, biguanides, DPP-4 inhibitors, SGLT2 inhibitors, and others).

The second group consists of hyperglycemic agents (antagonists). A prominent example is glucagon. Unlike other medications, they increase glucose concentration and are used exclusively for the emergency management of severe hypoglycemia.

Mechanism of Insulin Action

Insulin exerts its effects not directly, but by binding to specific receptors on the cell surface. This triggers a complex cascade of intracellular reactions leading to two main outcomes:

Enhancement of glucose transport. In insulin-dependent tissues (such as muscle and adipose tissue), specific GLUT-4 transporters undergo translocation. They move from the cytoplasm to the cell membrane and actively uptake sugar from the blood.
Alteration of intracellular metabolism. The hormone activates glycolysis enzymes, accelerating glucose utilization for energy production. Simultaneously, glycogen synthase—the enzyme responsible for glycogen synthesis—is stimulated, allowing glucose to be stored in the liver and skeletal muscles.

Notably, insulin does not affect carbohydrate absorption in the intestine nor does it enhance renal glucose excretion (these mechanisms are characteristic of other drug classes).

Stimulators of Endogenous Insulin Secretion

In type 2 diabetes mellitus, oral medications are frequently used to prompt pancreatic beta cells to produce more of their own insulin. Such secretagogues include:

Sulfonylureas (e.g., glibenclamide).
Meglitinides (glinides). A typical representative is nateglinide, a phenylalanine derivative. It selectively blocks ATP-dependent potassium channels in beta cells. The drug enhances the early phase of glucose-stimulated insulin secretion, provides a short insulin response, and is well-suited for preventing postprandial hyperglycemia (blood sugar spikes after meals).
Incretin mimetics and enhancers. This group includes glucagon-like peptide-1 (GLP-1) receptor agonists, which stimulate glucose-dependent secretion, as well as dipeptidyl peptidase-4 (DPP-4) inhibitors known as gliptins (e.g., saxagliptin).

Agents with Extra-Pancreatic Action

Some oral agents do not exhaust the pancreas; instead, they target other links in metabolic pathways:

Biguanides. The primary representative of this group is metformin. Unlike sulfonylureas, it does not stimulate insulin production at all. Its role is to reduce insulin resistance, thereby increasing the sensitivity of peripheral tissues to existing insulin.
Alpha-glucosidase inhibitors. A representative of this group is acarbose, which is chemically a tetrasaccharide. The drug works exclusively in the lumen of the small intestine and is poorly absorbed into systemic circulation. It competitively blocks the alpha-glucosidase enzyme, delaying and reducing the absorption of glucose from complex dietary carbohydrates. The major drawback of this mechanism is dyspeptic symptoms (diarrhea, flatulence) caused by the fermentation of unabsorbed carbohydrates by the intestinal microflora.

Mnemonic

To avoid confusing oral agent mechanisms: Biguanides = Baseline sensitivity improvement (no stimulation), while Sulfonylureas = Secretion of insulin.

Frequently asked questions

What specific drugs belong to the sulfonylurea class?

The sulfonylurea class includes the following specific drugs:

Glibenclamide (including micronized).
Gliclazide (including modified-release gliclazide).
Glimepiride.
Gliquidone.

Sulfonylureas stimulate insulin secretion. Advantages of this group include rapid glucose-lowering effects and low cost, while disadvantages include the risk of hypoglycemia, rapid development of resistance, and weight gain.

What is the mechanism of action of SGLT2 inhibitors (flozins)?

The mechanism of action of SGLT2 inhibitors involves blocking sodium-glucose cotransporter 2 in the proximal renal tubules. This leads to reduced reabsorption of glucose and sodium, leaving them in the primary urine. Consequently, sodium and glucose remain in the urine and draw water along with them, causing diuresis and natriuresis. This mechanism is insulin-independent and additionally promotes weight loss. The drug effect is mild, constant, does not cause severe dehydration, and does not activate the renin-angiotensin-aldosterone system.

What insulin preparations are classified based on their duration of action?

Based on their duration of action, insulin preparations are divided into the following groups:

Rapid-acting insulins — insulin analogs: insulin lispro, insulin aspart, insulin glulisine.
Short-acting insulins — e.g., regular human insulin.
Intermediate-acting insulins — e.g., neutral protamine Hagedorn (NPH) insulin / isophane insulin.
Long-acting / prolonged-acting insulins — e.g., insulin glargine, insulin detemir.

What is the full mechanism of action of GLP-1 receptor agonists?

The mechanism of action of GLP-1 receptor agonists includes a combined effect on metabolism and digestion:

Glucose-dependent insulinotropic effect — enhanced insulin production in response to glucose.
Reduction of glucagon secretion — glucose-dependent suppression, leading to decreased hepatic glucose production.
Delayed gastric emptying — helps reduce postprandial glycemia.
Decreased food intake — leads to weight loss and improved insulin resistance.
Reduction of de novo lipogenesis — accompanied by lowered serum transaminase levels.

How exactly does insulin prompt cells to take up glucose?

After binding to specific receptors, insulin triggers the movement of GLUT-4 transporter proteins from the cytoplasm to the cell membrane. Once on the surface, these transporters actively uptake glucose into adipose and muscle tissue.

What is the fundamental difference between biguanides and sulfonylureas?

Sulfonylureas directly stimulate pancreatic beta cells to release more insulin. Biguanides do not affect secretion; instead, they combat insulin resistance by increasing tissue sensitivity to the hormone.

Why does acarbose frequently cause abdominal bloating?

Acarbose blocks enzymes that break down carbohydrates in the small intestine. As a result, un digested sugars reach the large intestine, where local microflora actively ferment them, producing large amounts of gas.

Why are glucagon preparations used in diabetology?

Glucagon is a physiological antagonist of insulin and acts as a hyperglycemic agent. It is administered in emergency situations to rapidly raise blood sugar levels and treat severe hypoglycemia.

Go deeper

Mechanism of action of flozins (SGLT2 inhibitors) and renal glucose excretion.
Pharmacokinetics and adverse effects of sulfonylureas.
Differences in the mechanisms of action between GLP-1 agonists and DPP-4 inhibitors.
Intracellular signaling cascade upon insulin receptor activation.
Special considerations for insulin therapy in type 2 diabetes mellitus.